The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Roche
Research Funding - Baxter (Inst); Bayer (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Foundation Medicine (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); ONYX (Inst); Placon (Inst); Stem Cells, Inc. (Inst)
 
Claire F. Verschraegen
No Relationships to Disclose
 
Amy M. Weise
No Relationships to Disclose
 
John Sarantopoulos
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Fulgent Genetics; Genentech/Roche; Merck; Novartis; Pfizer; Sun Pharma; Takeda
 
Gilberto Lopes
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Merck Sharp & Dohme (Inst)
 
John J. Nemunaitis
Employment - Gradalis; Gradalis (I); US Oncology; US Oncology (I)
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca; Symvivo
Speakers' Bureau - Amgen; AstraZeneca
Research Funding - Gradalis
Patents, Royalties, Other Intellectual Property - Gradalis
Expert Testimony - Foundation Medicine
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Gradalis; Symvivo
 
Christine Hicking
Employment - Merck Serono
 
Jamie Shaw
Employment - Merck Serono
 
Remigiusz Kaleta
Employment - Merck Serono
 
Razelle Kurzrock
Leadership - CureMatch
Stock and Other Ownership Interests - CureMatch
Consulting or Advisory Role - Actuate Therapeutics; Loxo; Sequenom
Speakers' Bureau - Roche
Research Funding - Foundation Medicine (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Merck Serono (Inst); Pfizer (Inst); Sequenom (Inst)